N-Myc promotes therapeutic resistance development of neuroendocrine prostate cancer by differentially regulating miR-421/ATM pathway

BACKGROUND: MYCN amplification or N-Myc overexpression is found in approximately 40% NEPC and up to 20% CRPC patients. N-Myc has been demonstrated to drive disease progression and hormonal therapeutic resistance of NEPC/CRPC. Here, we aim to identify the molecular mechanisms underlying the N-Myc-dri...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Mol Cancer
Main Authors: Yin, Yu, Xu, Lingfan, Chang, Yan, Zeng, Tao, Chen, Xufeng, Wang, Aifeng, Groth, Jeff, Foo, Wen-Chi, Liang, Chaozhao, Hu, Hailiang, Huang, Jiaoti
Formato: Artigo
Idioma:Inglês
Publicado: BioMed Central 2019
Assuntos:
Research
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC6337850/
https://ncbi.nlm.nih.gov/pubmed/30657058
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12943-019-0941-2
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares